Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed ...

The financial results for Anteris for the year ended December 31, 2024 are reviewed below. All amounts in $ refer to U.S. dollars. In 2024, Net Sales were $2.7 million relating to sales of our tissue ...

Division of Corporation Finance announced that it has expanded its confidential filing process for certain draft registration statements submitted for nonpublic review. Since 2012, many issuers have ...

In January 2025, the Securities and Exchange Commission (the Commission) approved amendments to the minimum bid price ...

Newsmax Inc. (“Newsmax” or the “Company”) today announced the launch of its initial public offering (IPO) under Regulation A+, inviting investors nati ...

Discover Monster Beverage's growth strategies amidst fierce competition. Explore market trends, challenges, and MNST stock's ...

Strong returns in U.S. stocks, particularly over the past two plus years, have led investors to question the relative lack of ...

Despite reporting positive Phase II results for its lead candidate last year, Vaccinex will soon no longer be a publicly ...

There is a healthy pipeline of U.S. initial public offerings, but investors are looking for more certainty in markets, Adena ...

Docebo's Q4 2024 results beat revenue and earnings estimates, but forward revenue growth guidance has become tepid. Explore ...

Additionally, as a result of the Company’s market value of publicly held shares being $5,000,000 or above during the same period, the Company has regained compliance with Nasdaq Listing Rule 5450 (b) ...

Company receives approval for Nasdaq or NYSE listing after Beijing’s pledge to help more mainland companies raise funds.